ЛИМФОИДНЫЕ НЕОПЛАЗИИ ПОСЛЕ АЛЛОГЕННЫХ ТРАНСПЛАНТАЦИЙ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК. СЛУЧАЙ РАЗВИТИЯ ВТОРИЧНОЙ ЛИМФОМЫ ХОДЖКИНА, ДИФФЕРЕНЦИАЛЬНАЯ ДИАГНОСТИКА С ПОСТТРАНСПЛАНТАЦИОННЫМ ЛИМФОПРОЛИФЕРАТИВНЫМ ЗАБОЛЕВАНИЕМ

Вторичные злокачественные заболевания являются одними из наиболее угрожающих отдаленных эффектов трансплантации гемопоэтических стволовых клеток (ТГСК). В статье описана группа вторичных лимфоидных неоплазий, а также приведен редкий клинический случай развития вторичной лимфомы Ходжкина у пациента 21 года через 6 лет после аллогенной ТГСК по поводу острого миелобластного лейкоза. Данное осложнение необходимо дифференцировать с подобным лимфоме Ходжкина посттрансплантационным лимфопролиферативным заболеванием, так как подходы к их терапии и прогнозы различны. Приведены основные отличия данных патологий и способы проведения их дифференциальной диагностики. 

1. Deeg H.J., Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998,91:1833–44. PMID: 9490664.

2. Inamoto Y., Shah N.N., Savani B.N. et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant 2015,50(8):1013–23 DOI: 10.1038/bmt.2015.63. PMID: 25822223.

3. Majhail N.S. Old and new cancers after hematopoietic-cell transplantation. Hematology Am Soc Hematol Educ Program 2008:142–9. DOI: 10.1182/asheducation-2008.1.142. PMID: 19074072.

4. Penn I., Hammon W., Brettschneider L. et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969,1:106–12. PMID: 4944206.

5. Cockfield S.M. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001,3(2):70–8. PMID: 1139597247.

6. Baker K.S., DeFor T.E., Burns L.J. et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003,21(7):1352–8. Erratum in: J Clin Oncol 2003,21(16):3181. DOI: 10.1200/JCO.2003.05.108. PMID: 12663726.

7. Orazi A., Hromas R.A., Neiman R.S. et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997,107: 419–29. PMID: 9124210.

8. Hoover R.N. Lymphoma risks in populations with altered immunity — a search for mechanism. Cancer Res 1992,52:5477s. PMID: 1394157.

9. Cohen J.I. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991,70:137–60. PMID: 1848644.

10. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998,338:1413–21. DOI: 10.1056/NEJM199805143382003. PMID: 9580648.

11. Nalesnik M.A., Makowka L., Starzl T.E. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988,25:367–72. PMID: 3063441.

12. Leblond V., Davi F., Charlotte F. et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998,16(6):2052–9. PMID: 9626203.

13. Gong J.Z., Bayerl M.G., Sandhaus L.M. et al. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol 2006,30(3):328–36. DOI: 10.1097/01.pas.0000188030.63706.e7. PMID: 16538052.

14. Brunstein C.G., Weisdorf D.J., DeFor T. et al. Marked increased risk of EpsteinBarr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006,108(8):2874–80. DOI: 10.1182/blood-2006-03-011791. PMID: 16804113.

15. Snyder M.J., Stenzel T.T., Buckley P.J. et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004,28(6):794–800. PMID: 151666725.

16. Bollard C.M., Rooney C.M., Heslop H.E. T-cell therapy in the treatment of posttransplant lymphoproliferative disease. Nat Rev Clin Oncol 2012,9(9):510–29. Epub 2012 Jul 17. Review. DOI: 10.1038/nrclinonc.2012.111. PMID: 22801669.

17. Rowlings P.A., Curtis R.E., Passweg J.R. et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol 1999,17(10):3122–7. PMID: 10506608.

18. GrulichA.E.,VanLeeuwenM.T.,FalsterM.O. et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet 2007,370(9581):59–67. Review. DOI: 10.1016/S0140-6736(07)61050-2. PMID: 17617273.

19. Gottschalk S., Rooney C.M., Heslop H.E. Post-transplant lymphoproliferative disorders. Annu Rev Med., 2005,56:29–44. DOI: 10.1146/annurev.med.56.082103.104727. PMID: 15660500.

20. Loren A.W., Porter D.L., Stadtmauer E.A. et al. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003,31(3):145–55. DOI: 10.1038/sj.bmt.1703806. PMID: 12621474.

21. Dierickx D., Tousseyn T., Sagaert X. et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 2013,54(11):2433–40. DOI: 10.3109/10428194.2013.780655. PMID: 23442063.

22. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant 2004,4(Suppl.10):59–65. DOI: 10.1111/j.1600-6135.2004.00728.x. PMID: 15504214.

23. Luskin M.R., Heil D.S., Tan K.S. et al. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. Am J Transplant 2015,15(10):2665–73. DOI: 10.1111/ajt.13324. PMID: 25988622.

24. Jaffe E.S., Harris N.L., Stein H. et al. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours, vol. 3. Lyon, France: IARC Press, 2001. P. 264–9.

25. Dierickx D., Tousseyn T., Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood 2015,126(20):2274–83. DOI: 10.1182/blood-2015-05-615872. PMID: 26384356.

26. Semakula B., Rittenbach J.V., Wang J. Hodgkin lymphoma-like posttransplantation lymphoproliferative disorder. Arch Pathol Lab Med 2006,130(4):558–60. DOI: 10.1043/1543-2165(2006)130[558:HLPLD]2.0.CO,2. PMID: 16594752.

27. Pitman S.D., Huang Q., Zuppan C.W. et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006,30(4):470–6. PMID: 16625093.

28. Rohr J.C., Wagner H.J., Lauten M. et al. Differentiation of EBV-induced posttransplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant 2008,12(4):426–31. DOI: 10.1111/j.1399-3046.2007.00816.x. PMID: 18466428.

29. Ranganathan S., Webber S., Ahuja S. et al. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma? Pediatr Dev Pathol 2004,7(4):348–60. DOI: 10.1007/s10024-003-1115-0. PMID: 14564542.

30. Tsao L., Hsi E.D. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007,131(8):1209–18. DOI: 10.1043/1543-2165(2007)131[1209:TCSOPL]2.0.CO,2. PMID: 17683183.

31. Krishnamurthy S., Hassan A., Frater J.L. et al. Pathologic and clinical features of Hodgkin lymphoma-like posttransplant lymphoproliferative disease. Int J Surg Pathol 2010,18(4):278–85. Erratum in: Int J Surg Pathol 2010,18(5):444. DOI: 10.1177/1066896909338597. PMID: 19578050.

32. Pitman S.D., Huang Q., Zuppan C.W. et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006,30(4):470–6. PMID: 16625093.

33. Takehana C.S., Twist C.J., Mosci C. et al. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. Nucl Med Commun 2014,35(3):276–81. DOI: 10.1097/MNM.0000000000000050. PMID: 24296883.